MedTrace Logo

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

NCT05636267 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2026-03-09

No results posted yet for this study

Summary

This is a phase Ib/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 and AK112 With or Without Chemotherapy for NSCLC patients.

Conditions

Interventions

DRUG

AK119

AK119 IV every 3 weeks.

DRUG

AK112

AK112 IV every 3 weeks.

DRUG

Pemetrexed

Pemetrexed IV every 3 weeks.

DRUG

Carboplatin

Carboplatin IV every 3 weeks.

Sponsors & Collaborators

Principal Investigators

  • Yilong Wu, PhD · Guangdong Provincial People's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-10
Primary Completion
2025-02-24
Completion
2025-04-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05636267 on ClinicalTrials.gov